Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 14/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577311 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL14874761 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL531912 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL532579 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL531911 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL12696971 | 0.87 | CETP (0.55) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL1529173 | 0.84 | CETP (0.54) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL20794243 | 0.81 | CETP (0.66) | CETPNR1I2PTGDR2 | |
| SCHEMBL12434748 | 0.80 | CETP (0.56) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL1529174 | 0.80 | CETP (0.50) | CETPNR1I2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | CETP, MTTP, APOB | CETP 1/4885NR1I2 111/4885PTGDR2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.